Effect of empagliflozin on ectopic fat stores and myocardial energetics in type 2 diabetes: the EMPACEF study - Gaborit, B.; Ancel, P.; Abdullah, A. E.; Maurice, F.; Abdesselam, I.; Calen, A.; Soghomonian, A.; Houssays, M.; Varlet, I.; Eisinger, M.; Lasbleiz, A.; Peiretti, F.; et al. (Cardiovascular diabetology, 2021)
Keywords: 31P-MRS; Adenosine triphosphate; Adipose Tissue - drug effects; Adipose Tissue - metabolism; Adipose Tissue - pathology; Angiology; Animals; Antidiabetics; Benzhydryl Compounds - adverse effects; Benzhydryl Compounds - therapeutic use; Biomarkers - blood; Blood Glucose - drug effects; Blood Glucose - metabolism; Cardiac function; Cardiology; Cardiology and cardiovascular system; Cardiomyocytes; Cardiovascular disease; Diabetes; Diabetes mellitus (non-insulin dependent); Diabetes Mellitus, Type 2 - drug therapy; Diabetes Mellitus, Type 2 - metabolism; Diabetes Mellitus, Type 2 - pathology; Diet; Disease Models, Animal; Double-Blind Method; Ectopic fat; Ejection fraction; Energy Metabolism - drug effects; Epicardial adipose tissue; France; Glucose; Glucose tolerance; Glucosides - adverse effects; Glucosides - therapeutic use; Glycated Hemoglobin - metabolism; Heart failure; Hematocrit; High fat diet; Human health and pathology; Humans; Ketones; Life Sciences; Liver; Liver - drug effects; Liver - metabolism; Liver - pathology; Magnetic resonance imaging; Medicine; Medicine & Public Health; Metabolism; Mice; Mice, Inbred C57BL; Myocardial energetics; Myocardium - metabolism; Myocardium - pathology; Non-alcoholic Fatty Liver Disease - metabolism; Non-alcoholic Fatty Liver Disease - pathology; Non-alcoholic Fatty Liver Disease - prevention & control; Nutrition research; Original Investigation; Pancreas; Pcr/atp; Placebos; Proton Magnetic Resonance Spectroscopy; SGLT2 inhibitors; Sodium-glucose cotransporter; Sodium-Glucose Transporter 2 Inhibitors - adverse effects; Sodium-Glucose Transporter 2 Inhibitors - therapeutic use; Spectrum analysis; Sucrose; Time Factors; Treatment Outcome; Weight Loss - drug effects; France; Germany; Pcr/atp; Ectopic fat; MRI; Myocardial energetics; P-MRS; SGLT2 inhibitors; Epicardial adipose tissue; 31P-MRS; 31 P-MRS; SGLT2 inhibitors.Epicardial adipose tissue.Ectopic fat.Myocardial energetics.Pcratp.P-31-MRS.MRI